Hottest News: Synchronoss Technologies (NASDAQ:SNCR), Time (NYSE:TIME), Caesars Acquisition Company (NASDAQ:CACQ), Lombard Medical (NASDAQ:EVAR)

Baker Hughes Incorporated (NYSE:BHI) shares advanced 1.44% in last trading session and ended the day at $43.80. BHI Gross Margin is 7.90% and its has a return on assets of -7.70%. Baker Hughes Incorporated (NYSE:BHI) quarterly performance is 6.80%.

Baker Hughes Incorporated (NYSE:BHI) said that, Private-equity firm Carlyle Group LP is in serious talks to buy a package of oilfield-services businesses from Halliburton Co. and Baker Hughes Inc. that could be valued at more than $7 billion, as the energy giants seek to overcome a Justice Department challenge to their planned merger.

Synchronoss Technologies, Inc. (NASDAQ:SNCR) ended the last trading day at $32.64. Company weekly volatility is calculated as 3.06% and price to cash ratio as 6.72. Synchronoss Technologies, Inc. (NASDAQ:SNCR) showed a weekly performance of 1.90%.

Synchronoss Technologies, Inc. (NASDAQ:SNCR) announced it will report its first quarter 2016 financial results after the U.S. financial markets close on Thursday, May 5, 2016.

On 15 April, Time Inc. (NYSE:TIME) shares advanced 0.46% and was closed at $15.16. TIME EPS growth in last 5 year was -37.60%. Time Inc. (NYSE:TIME) year to date (YTD) performance is -3.25%.

Time Inc. (NYSE:TIME) has launched a website called Live-Smart which aims to demystify smart technology. The website has been launched by Time Inc’s new venture unit.

Caesars Acquisition Company (NASDAQ:CACQ) shares advanced 8.10% in last trading session and ended the day at $7.07. CACQ has a return on assets of 2.90%. Caesars Acquisition Company (NASDAQ:CACQ) quarterly performance is 35.70%.

Lombard Medical, Inc. (NASDAQ:EVAR) caters to the Healthcare space. Its weekly performance is 37.04%. On the last day of trading company shares ended up at $1.48. Lombard Medical, Inc. (NASDAQ:EVAR) distance from 50-day simple moving average (SMA50) is 12.79%.

Lombard Medical, Inc. (NASDAQ:EVAR) was downgraded to “equal-weight” by analysts at Barclays. They now have a USD 2.5 price target on the stock.